Ovarian Cancer Articles

Is the Median All We Should Offer Our Patients?
Although median survival is a reasonable endpoint to highlight, it is only 1 of many relevant outcome factors to discuss, and, most important, this mathematical figure simply does not define the survival of any particular patient.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of olaparib tablets (Lynparza) as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. 
Immunotherapy Combos on Horizon for Ovarian Cancer
Several phase III studies are exploring immunotherapy combinations with the potential to disrupt the systemic treatment paradigm for patients with ovarian cancer. 
PARP Combinations Offer New Opportunities in Ovarian Cancer
PARP inhibitor combination regimens have the potential to enhance the relatively modest benefit offered by several monotherapy approaches used for the treatment of patients with ovarian cancer.
PARP Combos With Bevacizumab, Immunotherapy in Development for Ovarian Cancer Treatment
Rebecca C. Arend, MD, discussed novel combinations being investigated for the treatment of patients with ovarian cancer.
Expert Highlights PARP Inhibitor Advancements in Ovarian Cancer, Points to Future Combos
David O'Malley, MD, discusses the excitement surrounding PARP inhibitors for patients with ovarian cancer.
Immunotherapy Combinations Slated to Pave the Way in Ovarian Cancer Treatment
Kathleen Moore, MD, discusses combination strategies with immunotherapy for patients with ovarian cancer.
Prexasertib Promising in BRCA Wild-Type Ovarian Cancer
Prexasertib (LY2606368) induced a 29% response rate with acceptable tolerability in women with measurable, recurrent high-grade serous or high-grade endometrioid ovarian carcinoma.
Inheritance Matters: The Race to Prevent New Ovarian Cancer Cases
Emerging data have confirmed that ovarian cancer is a much more heterogeneous disease than previously recognized.
The FDA’s recent approvals of novel anti-PARP agents as maintenance therapy for patients with previously treated advanced ovarian cancer highlight an issue that has received inadequate attention in the peer-reviewed oncology literature.
Publication Bottom Border
Border Publication